Metin Kurtoğlu, M.D., Ph.D.

Co-founder, Vivosel

Third-generation physician trained at University of Miami and NIH. Employee #1 at Cartesian Therapeutics, where he led development of the world's first RNA-transfected CAR-T therapy for autoimmune disorders.

Biography

Dr. Metin Kurtoğlu is a third-generation physician with extensive training at the University of Miami and the National Institutes of Health (NIH). His career at the forefront of cell therapy innovation has positioned him as a leader in translational medicine.

As Employee #1 at Cartesian Therapeutics, Dr. Kurtoğlu led the development of the world's first RNA-transfected CAR-T therapy for autoimmune disorders—a groundbreaking approach that has the potential to revolutionize treatment for millions of patients worldwide.

His dual M.D./Ph.D. background provides a unique perspective that bridges clinical practice with cutting-edge research. At Vivosel, he applies this expertise to develop next-generation cell therapies that can be translated from bench to bedside.

Background

•M.D., University of Miami Miller School of Medicine
•Ph.D., Biomedical Sciences
•Research Fellowship, National Institutes of Health (NIH)

Key Achievements

•Employee #1 at Cartesian Therapeutics
•Led development of world's first RNA-transfected CAR-T therapy for autoimmune disorders
•Co-founder of Vivosel biotechnology
•Third-generation physician with NIH research background